Clinical study of anisodamine hydrobromide for intestinal stress response in painless colonoscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070775

Enrollment

Unknown

Registered

2023-04-23

Start date

2023-02-18

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

Group C:Anisodamine hydrobromide was not given before induction

Group A10:intravenous injection of 10mg anisodamine hydrobromide

Group A20:intravenous injection of 20mg anisodamine hydrobromide

Eligibility

Sex/Gender

All

Age

55 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged 55-65 years; BMI=30kg/m2; ASA ? or ?.

Exclusion criteria

Exclusion criteria: Sinus tachycardia; Sick sinus syndrome; Glaucoma and severe prostatic hyperplasia; Obstructive sleep apnea syndrome;More serious cardiopulmonary disease; History of allergy to the narcotic drugs used; Enteroscopy through the stoma fistula; Various reasons can not cooperate, etc.

Design outcomes

Primary

Measure	Time frame
The degree and number of cases of intestinal spasm;Addition of drugs;Detection of intestinal polyps;Adverse reactions;	—

Secondary

Measure	Time frame
General Patient Information;Induction time, examination time and recovery time;Hemodynamics;	—

Countries

China

Contacts

Public Contactsunnenghong

Weifang People's Hospital

liuweiwei370786@163.com+86 19906367668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026